Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
-
Apollo Silver Further Strengthens Board of Directors
-
Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025
-
Orca Energy Group Inc. Announces Prepayment of International Finance Corporation Loan, Settlement of Supplementary Gas Sales Agreement and Judgment of the Tanzanian High Court
-
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers
-
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
-
WeRide’s Latest Robotaxi GXR to Start First Fully Unmanned Commercial Operations in Beijing
-
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
-
iHerb Surpasses $2.4 Billion in Sales, Solidifying Leadership in Global Health and Wellness
-
Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors
-
Rapport Therapeutics to Participate in Upcoming Investor Conferences
-
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
-
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer
-
Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives
-
OTC Markets Group Welcomes ZRCN Inc. to OTCQX
-
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
-
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
-
PyroGenesis Signs $2.4 Million Contract with Norsk Hydro ASA
-
OTC Markets Group Welcomes Anaergia Inc. to OTCQX
-
CareCloud to Announce Fourth Quarter and Full Year 2024 Results on March 13, 2025
-
C4 Therapeutics to Participate in Upcoming March Investor Conferences
-
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
-
Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025
-
Avalo Therapeutics to Participate in Upcoming Investor Conferences
-
Signify share repurchase period update
-
Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference
-
Kaspi.kz 4Q and FY 2024 Financial Results
-
MAG Provides Exploration Update and Outlook for Larder and Deer Trail Projects
-
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
-
Brown & Brown, Inc. names Stephen P. Hearn as executive vice president and chief operating officer
-
BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025
-
Brown & Brown, Inc. names Stephen P. Hearn as executive vice president and chief operating officer
-
Studio City Announces Earnings Release Date
-
Melco Announces Earnings Release Date
-
Net Asset Value(s)
-
Veri Medtech (VRHI) Reaches 1.3 million Patient Registrations
-
CampDoc and Traction Rec Partnership Elevates Community-Based Programs
-
A.I.S. Resources Announces Private Placement Financing, Shares for Debt Transaction and Appoints Marc Enright-Morin as President and Chief Executive Officer
-
Azimut Announces Results of the Annual General Meeting
-
Hyperscale Data Engages Northland Capital Markets to Explore Strategic Options for Michigan Data Center
-
Cycurion (NASDAQ: CYCU) Expands Cybersecurity Partnership with Leading National Public Health Association
-
Issue of Equity
-
Bitget Lists Zoo Adding it to Spot Trading
-
Bitget Announces Pre-Market Trading for Memhash (MEMHASH)
-
Bitget Introduces Bank Deposits with Callpay Integration, Enabling ZAR Access for South African Users
-
Beyond, Inc. Closes on the Purchase of Buy Buy Baby
-
Heineken Holding N.V. reports transactions under its current share buyback programme
-
Prime’s Fresnillo Generative Target Extended by 120 metres
-
Gran Tierra Energy Inc. Announces 2024 Fourth Quarter & Year-End Results
-
BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years
